文献速递心力衰竭与心肌病冠心病心律失常

钠-葡萄糖协同转运蛋白2抑制剂在心血管疾病谱中的获益

Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.
PubMed 文献 · Heart · 2021-05-10

本综述汇总SGLT2i在心血管结局试验中的证据,涵盖射血分数降低和保留的心力衰竭、2型糖尿病合并动脉粥样硬化性心血管疾病、心房颤动及慢性肾脏病等场景。SGLT2i可降低心衰住院和死亡率,被视为心衰药物治疗的第四大支柱,并在多种心血管疾病中显示获益。

要点

  • SGLT2i是射血分数降低心衰药物治疗的第四大支柱,无论是否合并糖尿病均可降低住院和死亡。
  • 在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,SGLT2i可减少主要不良心血管事件。
  • SGLT2i具有肾脏保护作用,但急性心衰、心梗后及晚期慢性肾脏病中的安全性尚待明确。

核心结论

  • SGLT2i在伴或不伴2型糖尿病的心血管疾病患者中均显示积极心血管效应,支持扩大临床应用以降低死亡并改善生活质量。

研究设计与样本

  • 本综述汇总近期SGLT2i心血管结局试验证据,聚焦其在各类心血管疾病中的应用。

主要发现

  • 在射血分数降低的心力衰竭中,SGLT2i无论是否合并糖尿病均可减少住院和死亡。
  • 近期试验数据提示SGLT2i在射血分数保留的心力衰竭中亦有良好效果。
  • 在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,多项心血管结局试验显示主要不良心血管事件减少。
  • 对这些试验的荟萃分析显示,SGLT2i可降低新发和复发心房颤动的发生率。
  • 试验显示SGLT2i具有肾脏保护作用,缓解了慢性肾脏病患者使用的担忧。

临床怎么用

  • SGLT2i应作为射血分数降低心衰的标准治疗支柱之一,不因是否合并糖尿病而限制使用。
  • 对2型糖尿病合并动脉粥样硬化性心血管疾病患者,可考虑使用SGLT2i以降低主要不良心血管事件。
  • SGLT2i可用于降低新发和复发心房颤动风险,并具有肾脏保护作用。
  • 急性心衰、心梗后及晚期慢性肾脏病患者使用SGLT2i的安全性尚待明确,需谨慎评估。

局限性

  • SGLT2i在急性心衰设置和心肌梗死后立即使用的安全性仍存疑问。
  • SGLT2i在更晚期慢性肾脏病患者中的安全性尚不明确。
  • SGLT2i在心脏瓣膜病患者中的评估仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a class of medications with positive cardiovascular (CV) effects across a spectrum of patients with and without type 2 diabetes (T2D). In heart failure with reduced ejection fraction, there is clear evidence that SGLT2i reduce hospitalisations and mortality regardless of the presence of diabetes, and they are now recognised as the fourth pillar of pharmacological management. Recent trial data also indicate promising effects in heart failure with preserved ejection fraction. In patients with T2D and atherosclerotic CV diseases, multiple CV outcomes trials have shown reductions in major adverse CV events. Meta-analysis of these trials also shows lower rates of incident and recurrent atrial fibrillation with SGLT2i. Concerns regarding utilisation in patients with chronic kidney disease have been allayed in trials showing SGLT2i in fact have renoprotective effects. Questions still remain regarding the safety of SGLT2i in the acute heart failure setting and immediately post myocardial infarction, as well as in patients with more advanced stages of chronic kidney disease. Furthermore, studies are underway evaluating SGLT2i in patients with heart valve disease, where positive effects on left ventricular remodelling may, for example, improve functional mitral regurgitation. In this review, we summarise the available evidence of recent CV outcomes trials of SGLT2i, focusing particularly on the application of these agents across various CV diseases. We detail evidence to support increased utilisation of these drugs, which in many cases will reduce mortality and improve quality of life in patients routinely encountered by the CV specialist physician.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Gulsin GS, Graham-Brown MPM, Squire IB, et al. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart. 2021. PMID: 33972360. doi:10.1136/heartjnl-2021-319185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。